Latest News on AMGN

Financial News Based On Company


Advertisement
Advertisement

Boston Partners Sells 124,947 Shares of Amgen Inc. $AMGN

https://www.marketbeat.com/instant-alerts/filing-boston-partners-sells-124947-shares-of-amgen-inc-amgn-2026-11-20/
Boston Partners reduced its stake in Amgen Inc. by 19.6% in the third quarter, selling 124,947 shares while retaining 512,976 shares valued at approximately $216 million. Amgen reported strong quarterly earnings of $6.45 per share, exceeding estimates, with an 8.5% year-over-year revenue increase to $10.37 billion. Analysts maintain a "Hold" consensus rating for Amgen, with an average price target of $428.62, and the company also declared a quarterly dividend of $2.52 per share.

Biotech plans $600-million expansion in Thousand Oaks

https://www.toacorn.com/articles/biotech-plans-600-million-expansion-in-thousand-oaks/
Amgen received approval from the Thousand Oaks City Council for a $600-million expansion project, which includes a new four-story science and technology center at its Newbury Park headquarters. The 377,000-square-foot building, named Building 50, will aim for LEED Gold certification and represents a significant investment in the company's future, innovation, and the local community. This expansion is expected to create economic benefits and attract talent, complementing the city's downtown redevelopment efforts.

Johnson & Johnson’s $3.05 Billion Acquisition Delivers Early Returns as JNJ-6143 Shows Encouraging Early Efficacy

https://nai500.com/blog/2026/11/johnson-johnsons-3-05-billion-acquisition-delivers-early-returns-as-jnj-6143-shows-encouraging-early-efficacy/
Johnson & Johnson's $3.05 billion acquisition of Halda Therapeutics is showing early success as the core asset, JNJ-6143, achieved a 75% overall response rate in a Phase 1 prostate cancer trial. This promising early-stage data validates the acquisition and highlights Johnson & Johnson's strong R&D capabilities. Combined with new drug launches, a focus on pharmaceuticals and medical devices, and a 64-year streak of dividend increases, the company demonstrates strong innovation and shareholder return potential.

Amgen Inc. $AMGN Shares Newly Bought by Advisors Asset Management Inc.

https://www.marketbeat.com/instant-alerts/filing-amgen-inc-amgn-shares-newly-bought-by-advisors-asset-management-inc-2026-11-20/
Advisors Asset Management Inc. has acquired a new stake of 179,004 shares in Amgen Inc. (NASDAQ:AMGN) during the third quarter, valued at approximately $75.5 million. This stake represents 0.7% of Advisors Asset Management Inc.'s portfolio. Amgen recently reported strong quarterly earnings, beating analyst expectations with $6.45 per share and an 8.5% year-over-year revenue increase to $10.37 billion, and declared a quarterly dividend of $2.52 per share, equating to a 2.3% annual yield.

Amgen Inc. stock outperforms competitors despite losses on the day

https://www.marketwatch.com/data-news/amgen-inc-stock-outperforms-competitors-despite-losses-on-the-day-302bd639-eeb7b109072a?mod=goog_fin_scmw
Amgen Inc. (AMGN) shares fell 1.14% to $438.82 on Thursday, marking its sixth consecutive day of losses. Despite this, the stock managed to outperform the broader market, as the S&P 500 Index and Dow Jones Industrial Average experienced larger declines.
Advertisement

Sinda, McEwen, Amcor, Coeur Mining, and Hecla Mining Company stocks trade down, what you need to know

https://www.theglobeandmail.com/investing/markets/stocks/AMCR/pressreleases/8923966/sinda-mcewen-amcor-coeur-mining-and-hecla-mining-company-stocks-trade-down-what-you-need-to-know/
Several stocks, including Sinda, McEwen, Amcor, Coeur Mining, and Hecla Mining Company, experienced a downturn following hawkish Federal Reserve signals, a strong U.S. dollar, and weaker regional manufacturing data. These factors pressured metals and cyclical demand, with Fed minutes suggesting further rate hikes are likely and the dollar index nearing a 19-month high. The Philadelphia Fed also reported a decline in its November manufacturing index, while prices paid increased, contributing to the downward pressure on miners and cyclical packaging and metals companies.

Securitize Offers Anthropic-Linked Security Entitlements on Solana

https://www.securities.io/securitize-offers-anthropic-linked-security-entitlements-on-solana/
Securitize has launched tokenized security entitlements for Anthropic shares on Solana, allowing investors to gain exposure to the AI company without becoming registered shareholders. This offering, available since Anthropic's first day of public trading on November 19, 2026, includes economic and voting entitlements. Securitize aims to integrate tokenization into public market entries from day one, expanding its Securitize Stocks platform with extended trading hours and USDC settlement.

Securitize Tokenizes Anthropic Stock Onchain on First Day of Public Trading

https://quantisnow.com/insight/securitize-tokenizes-anthropic-stock-onchain-on-first-day-of-public-6800366
Securitize Stocks has expanded its tokenized equity platform to include Anthropic shares (NASDAQ: ANT) from its first day of public trading, alongside Amgen (NASDAQ: AMGN) and Fox Corporation (NASDAQ: FOXA). This addition brings Securitize's onchain equity offering to over 50 U.S. stocks. The release highlights product expansion for Securitize Corp. but does not disclose financial results or impact on earnings.

Viridian Therapeutics initiated at 'buy' by Bank of America with $47 price target

https://uk.finance.yahoo.com/news/viridian-therapeutics-initiated-buy-bank-174800432.html
Bank of America has initiated coverage of Viridian Therapeutics with a 'buy' rating and a $47 price target, anticipating strong commercial prospects for its thyroid eye disease treatments, Lumvoa and elegrobart. Lumvoa, a challenger to Amgen's Tepezza, is expected to capture over 70% of the market within two years, with peak sales forecast at $1.3 billion. Elegrobart, an investigational subcutaneous treatment for chronic patients, is modeled to achieve peak sales of $1.7 billion, with a regulatory submission anticipated in Q1 2027.

Viridian Therapeutics initiated at 'buy' by Bank of America with $47 price target

https://finance.yahoo.com/healthcare/articles/viridian-therapeutics-initiated-buy-bank-174800059.html
Bank of America has initiated coverage of Viridian Therapeutics with a 'buy' rating and a $47 price target, citing strong commercial prospects for its thyroid eye disease treatments, Lumvoa and elegrobart. Lumvoa, a challenger to Amgen's Tepezza, is expected to capture over 70% of the market within two years, with peak sales forecast at $1.3 billion. Elegrobart, an investigational subcutaneous treatment for chronic thyroid eye disease, is projected to achieve peak sales of $1.7 billion due to its at-home administration potential.
Advertisement

Securitize Corp. (SECZ) Adds Anthropic and Two Stocks to Tokenized Platform

https://www.tradingview.com/news/tradingview:4afbed5515e3e:0-securitize-corp-secz-adds-anthropic-and-two-stocks-to-tokenized-platform/
Securitize Corp. (SECZ) has expanded its Solana-based tokenized platform by adding Anthropic on its first day of public trading, along with established companies Amgen and Fox Corporation. This brings the total offering to over 50 tokenized U.S. equities, with tokens backed 1:1 by underlying shares. The platform also differentiates itself by offering trading beyond traditional market hours.

Piper Sandler maintains Amgen at Overweight, raises price target to $542 from $457

https://www.tradingview.com/news/tradingview:f9dda312676c0:0-piper-sandler-maintains-amgen-at-overweight-raises-price-target-to-542-from-457/
Piper Sandler has reiterated its "Overweight" rating for Amgen (AMGN) and increased its price target from $457 to $542, marking an 18.6% rise. This new target suggests a 22.1% upside from Amgen's closing price of $443.89 on November 18. Other recent analyst actions on Amgen show a range of ratings and price targets from various firms.

Piper Sandler raises Amgen stock price target on pipeline potential

https://www.investing.com/news/analyst-ratings/piper-sandler-raises-amgen-stock-price-target-on-pipeline-potential-93CH-5039318
Piper Sandler has increased its price target for Amgen Inc. to $542 from $457, maintaining an Overweight rating, due to the potential of new pipeline contributions from dazodalibep and Imdelltra. The firm also highlighted other pipeline opportunities and the strength of Amgen's base business in offsetting future exclusivity losses. This follows Amgen's strong third-quarter financial results, which led other analysts like UBS, RBC Capital, and Argus to also raise their price targets, though Freedom Broker downgraded the stock to Hold on valuation concerns.

Piper Sandler raises Amgen stock price target on pipeline potential By Investing.com

https://ca.investing.com/news/stock-market-news/piper-sandler-raises-amgen-stock-price-target-on-pipeline-potential-93CH-4970071
Piper Sandler has increased its price target for Amgen (NASDAQ:AMGN) to $542 from $457, maintaining an Overweight rating, citing the company's robust pipeline potential. The upward revision is attributed to the inclusion of dazodalibep and Imdelltra's contributions for Sjogren’s disease and small cell lung cancer, respectively. The firm also highlighted Amgen's strong fundamentals and the growth potential from existing products like Repatha, Tezspire, and Evenity.

DISCO, AbbVie Sign AND-Gated Bispecific Deal Worth Up to $2.5B

https://www.pharmexec.com/view/disco-abbvie-sign-gated-bispecific-deal
DISCO Pharmaceuticals has signed a strategic collaboration and option-to-license agreement with AbbVie to develop AND-gated bispecific therapeutics for solid tumors. DISCO will receive $40 million upfront and is eligible for up to $2.5 billion in milestones and royalties. This deal leverages DISCO's DISCOtech® surfaceome mapping platform to create therapies that selectively target tumor cells while minimizing harm to healthy tissue, building on a previous 2026 agreement with Amgen.
Advertisement

As Sanofi's Pompe drug shortage drags on, some patients struggle to access treatments

https://www.cnbc.com/2026/11/19/as-pompe-drug-shortage-drags-on-patients-struggle-to-get-treatments.html
A shortage of Sanofi's Pompe disease drugs, Lumizyme and Nexviazyme, has continued for over three months due to manufacturing issues at its Ireland facility, leaving some patients unable to receive critical bi-weekly infusions. Patients fear that these interruptions could lead to irreversible health declines, with one patient likening the experience to a severe flu. The FDA has cited Sanofi for manufacturing violations unrelated to the Pompe drugs, which the company says has contributed to the supply disruption.

Securitize Tokenizes Anthropic Stock Onchain on First Day of Public Trading

https://www.quantisnow.com/insight/securitize-tokenizes-anthropic-stock-onchain-on-first-day-of-public-6800366
Securitize Stocks, a platform by Securitize Corp. (NYSE: SECZ), has tokenized Anthropic shares (NASDAQ: ANT) on its first day of public trading. The platform also added Amgen (NASDAQ: AMGN) and Fox Corporation (NASDAQ: FOXA), expanding its onchain equity offerings to over 50 U.S. stocks. This move represents a product expansion for Securitize but does not imply direct share ownership for token holders.

GE HealthCare’s manganese contrast agent advances to phase 3

https://www.investing.com/news/company-news/ge-healthcares-manganese-contrast-agent-advances-to-phase-3-93CH-5038908
GE HealthCare announced that its investigational manganese-based MRI contrast agent, mangaciclanol, met the primary endpoint in Phase 2 of the LUMINA clinical trial and will now advance to Phase 3. The Phase 2 study demonstrated similar diagnostic preference to a gadolinium-based agent and was well-tolerated. This new agent offers a potential alternative to gadolinium, which is primarily sourced from China, while manganese is more readily available globally.

Viridian Therapeutics initiated at 'buy' by Bank of America with $47 price target

https://www.proactiveinvestors.com/companies/news/1102139/viridian-therapeutics-initiated-at-buy-by-bank-of-america-with-47-price-target-1102139.html
Bank of America has initiated coverage of Viridian Therapeutics (Nasdaq: VRDN) with a 'buy' rating and a $47 price target, driven by the strong commercial prospects of its thyroid eye disease treatments. The brokerage anticipates Lumvoa will capture significant market share due to its comparable efficacy and shorter treatment course compared to Amgen’s Tepezza. Additionally, Viridian's investigational subcutaneous treatment, elegrobart, shows promise for the largely undertreated chronic thyroid eye disease patient population.

AbbVie pays DISCO $40 million upfront in a bispecific cancer deal worth up to $2.5 billion more

https://mlq.ai/news/abbvie-pays-disco-40-million-upfront-in-a-bispecific-cancer-deal-worth-up-to-25-billion-more/
AbbVie has agreed to an upfront payment of $40 million to DISCO Pharmaceuticals for a bispecific cancer drug discovery collaboration aimed at solid tumors. The deal includes potential milestone payments of up to $2.5 billion, plus tiered royalties. This collaboration leverages DISCO's DISCOtech platform, which focuses on "AND-gated bispecifics" designed to selectively target cancer cells while minimizing harm to healthy tissue.
Advertisement

AbbVie Pays $2.54 Billion to Partner With Germany's Disco, Staking a Claim in Solid-Tumor Bispecific Antibodies

https://finance.biggo.com/news/d5aa9063-9e8d-4371-827c-847a96e23c7d
AbbVie has entered into an option and license agreement with Disco Pharmaceuticals, potentially worth up to $2.54 billion, to develop "AND-gated" bispecific antibodies for solid tumors. Disco will receive a $40 million upfront payment and milestone payments, focusing on research and discovery using its DiscoTech platform. This collaboration aims to create precision medicines that selectively target cancer cells while minimizing harm to healthy tissue, building on AbbVie's existing ventures in the bispecific antibody space.

Adagene doses first patient in phase 1 trial of ADG138

https://ca.investing.com/news/stock-market-news/adagene-doses-first-patient-in-phase-1-trial-of-adg138-93CH-4969381
Adagene Inc. (NASDAQ:ADAG) has announced that the first patient has been dosed in a phase 1 study for ADG138, a double-masked HER2×CD3 bispecific T-cell engager. The open-label study will assess the safety and preliminary efficacy of ADG138 in patients with HER2-positive advanced solid tumors, with dose escalation starting at 2 mg. Preclinical data for ADG138 showed reduced cytokine release, a longer apparent half-life, and tumor regression in various HER2 tumor models.

Amgen Inc (AMG.SG) Seasonal returns chart

https://uk.finance.yahoo.com/quote/AMG.SG/seasonality/
This article provides a seasonal returns chart for Amgen Inc (AMG.SG), showing the average monthly price return from 2016 to 2026. It notes that Amgen Inc announced a cash dividend of EUR 2.52 with an ex-date of November 20, 2026. The stock was trading at 404.05 EUR, up 1.00% as of 11:46:28 CET.

Disco Pharma Partners With AbbVie to Develop Bispecific Therapies for Solid Tumors

https://www.genomeweb.com/business-news/deals/collaboration/gnw-disco-abbvie-collaboration-bispecifics-20261119/
Disco Pharma has partnered with AbbVie to develop bispecific therapies aimed at treating solid tumors. The collaboration seeks to advance innovative treatments in the field of cancer diagnostics and precision medicine. This strategic alliance was announced on November 19, 2026.

MSD Wins All 14 U.S. Patent Trials Against Halozyme, Easing Patent Risk for Subcutaneous Keytruda

https://finance.biggo.com/news/5cbc8f34-39d5-40b8-9025-821acf3c2f3d
MSD has won all 14 U.S. patent invalidation challenges against Halozyme Therapeutics regarding its MDASE technology, which converts drugs to subcutaneous formulations. This decision significantly eases patent risk for Keytruda Qlex, MSD's subcutaneous cancer drug utilizing Alteogen's ALT-B4 technology, which recently received FDA approval and generated $830 million in Q3 sales. However, the dispute is not fully resolved as Halozyme may appeal the PTAB decision, and a related patent infringement lawsuit in federal court remains pending.
Advertisement

AbbVie grooves with DISCO’s solid tumor tech in up to $2.5B licensing deal

https://www.biospace.com/business/abbvie-grooves-with-discos-solid-tumor-tech-in-up-to-2-5b-licensing-deal
AbbVie has partnered with DISCO Pharmaceuticals in a licensing deal potentially worth $2.54 billion for its logic-based bispecific platform to develop solid tumor therapies. AbbVie will provide a $40 million upfront payment, with the remainder contingent on milestones. This collaboration marks DISCO's second major pharma partnership this year, highlighting its DISCOtech platform for targeted therapies.

After Amgen, DISCO lands AbbVie deal worth up to $2.5B

https://european-biotechnology.com/latest-news/after-amgen-disco-lands-abbvie-deal-worth-up-to-2-5b/
Cologne-based DISCO Pharmaceuticals has secured a cancer drug discovery deal with AbbVie, involving an upfront payment of $40 million and potential additional payments of up to $2.5 billion. This marks DISCO's second major pharma partnership this year, building on its January agreement with Amgen. The collaboration focuses on DISCO's proprietary DISCOtech platform, which identifies cancer targets by mapping surfaceome proteins and using an AND-gating mechanism for improved tumor selectivity.

Amgen falls 2.86% in Wednesday's session

https://www.globalbankingandfinance.com/amgen-amgn-falls-2026-11-18/
Amgen's shares experienced a 2.86% drop in value, closing at 444.86 USD on November 18, 2026. The decline from its previous close of 457.93 USD reduced the company's market capitalization to $240.09 billion within the United States health care sector. This report highlights the daily performance of Amgen's stock, noting it traded significantly below its prior closing price.

Amgen Inc Stock (AMGN) Moved Down by 3.21% on Nov 18: What Signal Does It Send?

https://www.tradingkey.com/news/market-movers/262311625-market-movers-amgn-20261118
Amgen Inc. (AMGN) shares fell by 3.21% due to institutional caution regarding its clinical pipeline and challenges from patent cliffs and regulatory pricing pressures. Investors are closely watching the competitive dynamics of its investigational asset, MariTide, and the impact of the Inflation Reduction Act. Technical indicators show a neutral MACD and RSI, with an oversold Williams %R, while analysts maintain an average "Hold" rating with an average price target of $422.26.

Building Obesity Care That Lasts

https://www.amgen.com/stories/2026/11/building-obesity-care-that-lasts
This article emphasizes that starting obesity treatment is just the beginning; patients need sustained support to navigate access, treatment demands, and daily challenges. It highlights the persistence gap in obesity management, with many patients discontinuing GLP-1 therapy within a year due to complex reasons beyond the treatment itself. The author advocates for a connected healthcare ecosystem that extends beyond scientific innovation to ensure patients can access and sustain care, ultimately defining success by improved long-term health outcomes beyond just weight loss.
Advertisement

55,181 Amgen Inc. $AMGN Shares Acquired by Cibc World Market Inc.

https://www.marketbeat.com/instant-alerts/filing-55181-amgen-inc-amgn-shares-acquired-by-cibc-world-market-inc-2026-11-18/
CIBC World Market Inc. significantly increased its stake in Amgen Inc. during the third quarter, acquiring 55,181 additional shares and bringing its total holdings to 120,866 shares valued at over $50.9 million. Amgen reported strong quarterly earnings, beating estimates with $6.45 EPS and $10.37 billion in revenue, an 8.5% year-over-year increase. The company also declared a quarterly dividend of $2.52 per share, while analysts maintain a "Hold" rating with an average price target of $425.69.

Olema Oncology Announces Preclinical Data Show Potent Oral KAT6A Degraders Inhibit ER+/HER2- Breast Cancer Growth

https://www.quiverquant.com/news/Olema+Oncology+Announces+Preclinical+Data+Show+Potent+Oral+KAT6A+Degraders+Inhibit+ER%2B%2FHER2-+Breast+Cancer+Growth
Olema Oncology reported promising preclinical data on its selective KAT6A degraders, showing strong antitumor activity and good tolerability in ER+/HER2- breast cancer models. These oral compounds demonstrated potent antiproliferative effects in both ESR1-mutant and wild-type models, leading to significant tumor growth inhibition and regression. The findings suggest KAT6A degradation could be a valuable new therapeutic strategy for breast cancer, complementing Olema's existing KAT6 inhibitor.

Novartis reports positive phase 3 data on ianalumab for Sjögren’s

https://glance.eyesoneyecare.com/stories/2026-11-17/novartis-reports-positive-phase-3-data-on-ianalumab-for-sjoegren-s/
Novartis announced positive long-term results from its phase 3 NEPTUNUS extension study for ianalumab in Sjögren’s disease (SD), presented at ACR Convergence 2026. Ianalumab, an investigational monoclonal antibody targeting BAFF-R, demonstrated sustained reductions in systemic disease activity and improvements in patient-reported measures with a favorable safety profile. The drug is currently under regulatory review in multiple countries, with an FDA decision anticipated this year.

Natera Short Interest Rises As Bets Remain Near September Peak

https://www.benzinga.com/trading-ideas/short-ideas/26/11/63355238/natera-short-interest-rises-as-bets-remain-near-september-peak
Natera Inc. (NASDAQ:NTRA) saw its short interest rise by 3.77% to 6.07 million shares as of October 30, 2026, representing 4.31% of the float. This level is just below the September 30 peak of 6.36 million shares. The company's shares were down 3.22% at $279.18 on Tuesday, significantly below its 52-week high.

Amgen Has Raised Its 2026 Outlook Twice, and $1,000 From Five Years Ago Is Now Worth More Than $2,500

https://247wallst.com/investing/2026/11/17/amgen-has-raised-its-2026-outlook-twice-and-1000-from-five-years-ago-is-now-worth-more-than-2500/
Amgen has raised its 2026 guidance twice due to strong performance from new drugs like Repatha, UPLIZNA, and IMDELLTRA, which are offsetting declines in older blockbusters like Prolia. An initial investment of $1,000 in Amgen five years ago would now be worth approximately $2,600, significantly outperforming the S&P 500. The company's future valuation largely depends on the success of its obesity candidate, MariTide, amidst competition and a substantial debt load.
Advertisement

Biogen’s anti-tau Alzheimer’s drug benefits increase at 2 years

https://kelo.com/2026/11/17/biogens-anti-tau-alzheimers-drug-benefits-increase-at-2-years/
New trial data shows that Biogen's experimental anti-tau Alzheimer's drug, diranersen, significantly slowed cognitive decline in early Alzheimer's patients after two years. The lowest dose (60-milligram twice-yearly) improved cognitive decline by 38%, an increase from the 26% reported at 18 months, making it the first tau-targeting drug to demonstrate such efficacy. Biogen is now discussing Phase 3 trial outlines with regulators and exploring potential combination therapies with amyloid-targeting drugs like Leqembi.

Should You Invest in the VanEck Biotech ETF (BBH)?

https://sg.finance.yahoo.com/news/invest-vaneck-biotech-etf-bbh-102002689.html
The VanEck Biotech ETF (BBH), launched in December 2011, is a passively managed ETF offering broad exposure to the Healthcare - Biotech segment. With an expense ratio of 0.35% and $521.91 million in assets, it has returned 31.47% year-to-date. BBH holds a Zacks ETF Rank of 2 (Buy) and is considered a high-risk option due to its concentrated holdings.

Eli Lilly & Co (LLY) Receives a Buy from Barclays

https://www.theglobeandmail.com/investing/markets/stocks/LLY-N/pressreleases/8869880/eli-lilly-co-lly-receives-a-buy-from-barclays/
Barclays analyst Emily Field maintained a Buy rating on Eli Lilly & Co (LLY) with a price target of $1,550.00. This aligns with a general Strong Buy consensus among analysts, with an average price target of $1,520.14 for the company. Eli Lilly & Co recently reported strong quarterly revenues of $24.4 billion and a net profit of $6.45 billion for the quarter ending September 30.

Collaboration revenue falls to $132K as Q3 losses widen at Cue Biopharma (CUE).

https://www.stocktitan.net/sec-filings/CUE/10-q-cue-biopharma-inc-quarterly-earnings-report-05afbf201886.html
Cue Biopharma (CUE) reported a significant widening of its net loss to $50.016 million in Q3 2026, up from $7.448 million a year prior, as collaboration revenue dropped to $132,000 from $2.149 million. The nine-month net loss expanded to $208.261 million, heavily impacted by a $90.011 million loss on liability-classified warrants and $59.362 million in stock-based compensation. The company ended the quarter with $57.939 million in cash and expects it to fund operations for at least the next 12 months, while continuing to advance its CUE-401 Phase 1 dosing and managing a potential $676.5 million in milestone payments from its Ascendant license for an anti-IgE candidate.

Uniquity’s Phase II Solrikitug Data In EoE Rival Amgen/AstraZeneca’s Tezspire

https://insights.citeline.com/scrip/r-and-d/clinical-trials/uniquitys-phase-ii-solrikitug-data-in-eoe-rival-amgenastrazenecas-tezspire-X6BLPV5XHFCBPD4G4DAYYIOU6A/
Uniquity Bio reported positive Phase II results for its TSLP inhibitor solrikitug in eosinophilic esophagitis (EoE), indicating it is at least as effective as Amgen and AstraZeneca’s Tezspire. The company plans to initiate a single Phase III clinical trial in early 2027, financed by Blackstone Life Sciences and potentially other investors, with the goal of supporting FDA approval. This move positions solrikitug as a significant contender in the EoE treatment landscape, which currently has only one approved biologic therapy.
Advertisement

European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

https://www.manilatimes.net/2026/11/17/tmt-newswire/globenewswire/european-commission-approves-revolution-medicines-rasonque-daraxonrasib-the-first-broad-ras-targeted-medicine-in-metastatic-pancreatic-cancer/2471319
The European Commission has approved Revolution Medicines' RASONQUE (daraxonrasib) for treating adult patients with metastatic pancreatic adenocarcinoma who have received prior systemic therapy. This marks the first broad RAS-targeted medicine approved in Europe for this aggressive cancer, including patients with or without a RAS tumor mutation. The approval is based on positive results from the Phase 3 RASolute 302 clinical trial, which demonstrated significant survival benefits.

Polaryx Therapeutics, Inc. (1V8.F) stock price, news, quote and history

https://au.finance.yahoo.com/quote/1V8.F/earnings-calls/
This article provides a comprehensive overview of Polaryx Therapeutics, Inc. (1V8.F) stock, including its current price, news, and historical data. As of November 17, the stock closed at 1.5620 EUR, up 2.36%. The company, a clinical-stage biotechnology firm, focuses on developing therapies for rare and pediatric lysosomal storage disorders.

Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)

https://www.globenewswire.com/news-release/2026/11/17/3404251/0/en/novartis-cosentyx-becomes-first-and-only-fda-approved-anti-il-17-biologic-for-people-with-polymyalgia-rheumatica-pmr.html
Novartis announced that its drug Cosentyx® (secukinumab) has received FDA approval for treating adult patients with polymyalgia rheumatica (PMR) who inadequately respond to or cannot tolerate corticosteroids. This makes Cosentyx the first and only anti-interleukin-17 biologic approved for PMR, offering a new treatment option beyond long-term steroid use, which is the current standard of care but carries significant side effects. The approval is based on the Phase III REPLENISH trial, where Cosentyx 150 mg doubled sustained remission rates compared to placebo and demonstrated steroid-sparing effects.

Europe approves the first once-daily pill for eligible adults with a chronic, painful skin disease.

https://www.stocktitan.net/news/INCY/povofortay-povorcitinib-approved-in-europe-as-the-first-once-daily-wtpdd3wpecar.html
The European Commission has approved Incyte's Povofortay (povorcitinib) as the first once-daily oral treatment for eligible adults with moderate to severe hidradenitis suppurativa (HS). This approval is based on Phase 3 STOP-HS1 and STOP-HS2 trials, which demonstrated the drug's efficacy and tolerability over 54 weeks. The U.S. Food and Drug Administration is also reviewing povorcitinib, with a potential approval and launch in the first quarter of 2027.

Pharvaris N.V. Ransomware Attack by N0n

https://socradar.io/free-tools/ransomware-intelligence/victims/pharvaris-n-v-n0n-a915c939
Pharvaris N.V., a healthcare company based in the Netherlands, has been subjected to a ransomware attack by the n0n threat group. The attack was discovered on November 16, 2026, and the n0n group has claimed responsibility. This incident is part of a broader campaign by n0n, which has targeted 205 victims across various sectors, including healthcare, since September 2026.
Advertisement

Verastem, Inc. Ransomware Attack by N0n

https://socradar.io/free-tools/ransomware-intelligence/victims/verastem-inc-n0n-05dab8da
Verastem, Inc., a biopharmaceutical company, has been identified as a victim of a ransomware attack by the "n0n" group. The attack was discovered on November 16, 2026, with a 100% confidence level and medium severity. The n0n group, which has been active since September 2026, has claimed 203 victims to date and frequently targets the healthcare industry.

|‘Ahead of its peers in clinical development’: Fan on Fate Therapeutics

https://www.bnnbloomberg.ca/video/shows/the-open/2026/11/16/ahead-of-its-peers-in-clinical-development-fan-on-fate-therapeutics/
Martin Fan, Vice President of Equity Research at Wedbush, discussed Fate Therapeutics as one of his top picks in the biotech sector. He highlighted the company's advanced position in clinical development compared to its competitors. This interview took place on BNN Bloomberg, where Fan shared his insights on promising biotech investments.

ADARx Pharmaceuticals: Deep, durable siRNA programs approach pivotal HAE and multiple 2027 readouts

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4640033:0-adarx-pharmaceuticals-deep-durable-sirna-programs-approach-pivotal-hae-and-multiple-2027-readouts/
ADARx Pharmaceuticals' siRNA platform shows deep and durable knockdown, with Phase III enrollment for HAE potentially completing ahead of Q1 2027 guidance and data expected by late 2027. The company also plans mid-to-late 2027 readouts for its Factor B program, while Factor XI and obesity programs continue to advance. This information is based on their UBS Global Biopharma Conference 2026 audio transcript from November 16, 2026.

Russell Investments Group Ltd. Sells 346,461 Shares of Crown Castle Inc. $CCI

https://www.marketbeat.com/instant-alerts/filing-russell-investments-group-ltd-sells-346461-shares-of-crown-castle-inc-cci-2026-11-15/
Russell Investments Group Ltd. has reduced its stake in Crown Castle Inc. (NYSE:CCI) by 19.9% in the third quarter, selling 346,461 shares but retaining 1.39 million shares worth approximately $92.8 million. Crown Castle reported third-quarter EPS of $0.67, missing consensus estimates, and revenue of $995 million, a 7.2% year-over-year decline. Despite the earnings miss, the company declared a quarterly dividend of $1.0625 per share, representing an annualized yield of 4.7%.

Read This Before Considering Amgen Inc. (NASDAQ:AMGN) For Its Upcoming US$2.52 Dividend

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amgn/amgen/news/read-this-before-considering-amgen-inc-nasdaqamgn-for-its-up-2
Amgen Inc. (NASDAQ:AMGN) is set to go ex-dividend in the next four days, with a payment of US$2.52 per share. The company's dividend yield is approximately 2.2%, and its dividend payments are covered by both profits (57% payout ratio) and free cash flow (56% payout ratio). While earnings per share have grown by 7.0% annually over the last five years, the high payout ratio might limit future reinvestment and dividend growth.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement